RT Journal Article
SR Electronic
T1 Risk factors for disseminated intravascular coagulation (DIC) in patients with lung cancer
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP PA2135
DO 10.1183/13993003.congress-2016.PA2135
VO 48
IS suppl 60
A1 Kentaro Nakano
A1 Kumiya Sugiyama
A1 Takayoshi Fujimatsu
A1 Naruo Yoshida
A1 Ryosuke Souma
A1 Masamitsu Tatewaki
A1 Kenya Kohyama
A1 Hirokuni Hirata
A1 Yasutsugu Fukushima
YR 2016
UL http://erj.ersjournals.com/content/48/suppl_60/PA2135.abstract
AB Background: Treatment of DIC in lung cancer (LC) is considered more difficult than in other lung diseases, but it has not been clarified.Aims: To elucidate the risk factors for DIC in LC, we analyzed blood coagulation test data for patients with LC and patients with other lung disease.Methods: Subjects were 10 patients without DIC (9 men, 1 woman; mean age, 69.5 years): 6 had LC (3 adeno, 2 squamous cell, 1 small cell) and 4 had other lung disease (2 chronic obstructive pulmonary disease and 2 interstitial pneumonia). Background characteristics did not significantly differ between the groups.Results: Compared with patients with other lung disease, LC patients had higher values for fibrinogen (590.3 mg/dl vs 450.5 mg/dl), antithrombin III (105.5% vs 96.3%), activated protein C (101.7% vs 76.8%), activated plasminogen (101.3% vs 89.0%), tissue plasminogen activator inhibitor-1 (27.8 ng/ml vs 19.5 ng/ml), and thrombin-antithrombin III complex (5.9 ng/ml vs 3.3 ng/ml)and lower values for D-dimer (0.86 ug/mL vs 4.39 ug/mL), fibrin degradation products(3.93 ug/mL vs 10.1 ug/mL), and thrombomodulin (3.0 FU/ml vs 3.3 FU/ml). These differences were not significant because of the small sample number. No patients have developed DIC to date.Conclusion: In DIC, blood coagulation is promoted and protein C coagulation suppressed. In LC patients, we found a trend for the former to be suppressed and the latter to be promoted, suggesting we may be able to treat DIC that occurs in LC patients more effectively.We are continuing to enroll new subjects without DIC and to follow-up enrolled subjects for progression of DIC in our ongoing study. We will present the final results at ERS 2016.